Back to News
Market Impact: 0.25
Lakewood-Amedex Secures IRB Approval To Begin Nu-3 Phase 2a Study In Infected Diabetic Foot Ulcer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Lakewood-Amedex Biotherapeutics obtained central and site-level Institutional Review Board approvals and confirmed trial-site readiness to begin its Phase 2a clinical trial. The regulatory and operational milestones advance the clinical-stage biotech's development program, though no efficacy, safety, financial, or enrollment details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LABT0.60
More News
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros
- Canada’s BC sues OpenAI over ChatGPT role in Tumbler Ridge school shooting
- Paramount settles lawsuit blocking $110 billion Warner Bros. merger
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI for Sell-Side Models, Estimates, and Internal Data
- How to Write an Investment Memo with AI: A Decision-Record Template